In a clinical trial published in 2018, cholecalciferol supplementation (25,000 IU/week vs. placebo for 3 months), combined with a weight loss program, was found to significantly improve insulin sensitivity in metabolically healthy obese subjects, concluding that this therapeutic option could represent a personalized approach for obese subjects with insulin resistance [74]. The gene discussed is INS; the disease is Insulin resistance.